Intact plasma quantification of the large therapeutic lipopeptide bulevirtide

Bulevirtide is a first-in-class entry inhibitor of the hepatitis B and hepatitis delta virus blocking the sodium/bile acid co-transporter NTCP, and was recently approved for the treatment of hepatitis D as a priority medicine (prime) in an accelerated assessment by the European Medicines Agency. It...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauter, Max, Blank, Antje, Stoll, Felicitas, Lutz, Natalie, Haefeli, Walter E., Burhenne, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410713/
https://www.ncbi.nlm.nih.gov/pubmed/34018034
http://dx.doi.org/10.1007/s00216-021-03384-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410713/
https://www.ncbi.nlm.nih.gov/pubmed/34018034
http://dx.doi.org/10.1007/s00216-021-03384-7

Ejemplares similares